MIRUM PHARMACEUTICALS INC
NASDAQ: MIRM (Mirum Pharmaceuticals, Inc.)
Kemas kini terakhir: 1 jam lalu82.93
-0.99 (-1.18%)
| Penutupan Terdahulu | 83.92 |
| Jumlah Dagangan | 1,134,037 |
| Harga / Pendapatan (P/E Ke hadapan) | 166.67 |
| Harga / Jualan (P/S) | 8.11 |
| Harga / Buku (P/B) | 26.59 |
| Julat 52 Minggu |
| Margin Keuntungan | -20.39% |
| Margin Operasi (TTM) | -13.61% |
| EPS Cair (TTM) | -1.61 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 61.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 135.97% |
| Nisbah Semasa (MRQ) | 3.22 |
| Aliran Tunai Operasi (OCF TTM) | -6.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -23.97 M |
| Pulangan Atas Aset (ROA TTM) | -7.11% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Mirum Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.33 |
|
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.90% |
| % Dimiliki oleh Institusi | 114.19% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |